1.9.2015

ArcDia is developing pandemics preparedness

ArcDia has signed an agreement to develop diagnostic system to increse pandemic preparedness. The R&D activities of the cross-border project are financied by TEKES, the Finnish Funding Agency for Innovation and Russian organization FASIE. Read more here.

ArcDia has entered into an exclusive license agreement with Xinhua Healthcare for the commercialisation of ArcDia’s mariPOC® technology in China

mariPOC® ensures lower probability for C. difficile misdiagnosis with precision

New research data shows that influenza antigen testing correlates best with the infectivity period

Press release: New test for detection of C. difficile infection

New QuickStrepA

Study: Diagnosis of respiratory tract infections caused by human bocavirus 1

New mariPOC influenza A virus test with significantly improved sensitivity

New test for Flu A

World’s fastest antibiotic resistance testing

New mariPOC® Gastro test available

Detection and monitoring of human bocavirus 1 infection by a new rapid antigen test

ArcDia contributes solving the global problem of antimicrobial resistance

Press release: Spanish clinical study demonstrates mariPOC’s excellent performance

ArcDia is developing pandemics preparedness

The diagnostics of group A streptococcus from pharyngeal swab samples by bacterial culture is challenged by a novel mariPOC point of care test.

The Flu Season Has Begun – mariPOC® Helps

Nobel Prize awarded to mariPOC® sister technology

The Evolution of Rapid POC Tests for Infectious Disease Diagnostics: An Exclusive SelectScience Interview

ArcDia Receives Frost & Sullivan Award for Point-of-Care Product Leadership!

ArcDia launches world’s first antigen test for human bocavirus – Press Release

New press release

ArcDia is developing pandemics preparedness

ArcDia International Oy Ltd.

Links

Follow us

Do you want to receive mariPOC® newsletter?